文献速递痛风与晶体性关节病

双能CT测尿酸晶体沉积与痛风患者死亡及心血管风险相关

Crystal deposition measured with dual-energy computed tomography: association with mortality and cardiovascular risks in gout.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究纳入128例痛风患者,用双能CT测量膝和足部单钠尿酸盐晶体体积并随访。基线晶体体积与全因死亡风险相关(HR 1.02,95%CI 1.002–1.03),且是心血管代谢共病发生的唯一相关因素(HR 1.014,95%CI 1.001–1.03)。

要点

  • 双能CT测得的尿酸晶体体积与痛风患者全因死亡风险独立相关。
  • 晶体体积是心血管代谢共病新发的唯一相关因素。
  • 基线血尿酸水平也与死亡风险相关,但与共病发生无关。

核心结论

  • 双能CT测量的单钠尿酸盐晶体体积是痛风患者新发心血管代谢疾病和全因死亡风险的生物标志物。

研究设计与样本

  • 纳入128例确诊痛风且基线有膝和足部双能CT扫描的患者进行随访,用多变量Cox模型分析死亡和心血管代谢事件复合终点的危险因素。

主要发现

  • 随访期间14例死亡,其中6例死于心血管原因,17例出现新发心血管代谢共病。
  • 与死亡风险相关的因素为基线双能CT晶体体积(HR 1.02,95%CI 1.002–1.03)和基线血尿酸水平(HR 1.04,95%CI 1.003–1.06)。
  • 双能CT晶体体积是唯一与心血管代谢共病发生相关的因素(HR 1.014,95%CI 1.001–1.03)。

关键数值与推荐

  • 患者年龄66.1(14.0)岁,痛风病程11.4(10.4)年,61.7%未使用降尿酸治疗,随访24(12,36)个月。
  • 基线血尿酸7.44(2.29)mg/dl,双能CT晶体体积0.2(0,0.9)cm3。

临床怎么用

  • 对痛风患者可考虑用双能CT评估晶体体积,以识别心血管代谢共病和死亡高风险者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine whether the volume of monosodium urate (MSU) crystal deposition measured with dual-energy CT (DECT) is predictive of short-term mortality and development of cardiovascular comorbidities and diabetes mellitus. METHODS: Patients with a diagnosis of gout having had baseline DECT scans of their knees and feet to measure the volume of MSU crystal deposition were included to undergo a follow-up visit. Risk factors for mortality and a composite variable (onset of any cardio-metabolic event) were examined using multivariable Cox models. RESULTS: A total of 128 patients aged 66.1 (14.0) years with gout durations of 11.4 (10.4) years were included; most were naïve of urate lowering therapy (61.7%), with a follow-up visit at 24 (12, 36) months. Baseline serum urate (SU) level was 7.44 (2.29) mg/dl and DECT volume of MSU crystals was 0.2 (0, 0.9) cm3. A total of 14 patients died during follow-up, 6/14 from a cardiovascular cause, and 17 patients presented a new cardio-metabolic comorbidity. Factors associated with mortality risk were baseline DECT volume of MSU crystals [hazard ratio (HR) 1.02, 95% CI: 1.002, 1.03] and baseline SU level (HR 1.04, 95% CI: 1.003, 1.06). DECT volume of MSU crystals was the only factor associated with the onset of cardio-metabolic comorbidities with a HR of 1.014 (95% CI: 1.001, 1.03). CONCLUSIONS: Volume of MSU crystals measured with DECT is a biomarker for the risk of developing new cardio-metabolic diseases and for all-cause mortality.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Marty-Ané A, Norberciak L, Andrès M, et al. Crystal deposition measured with dual-energy computed tomography: association with mortality and cardiovascular risks in gout. Rheumatology (Oxford). 2021. PMID: 33410483. doi:10.1093/rheumatology/keaa920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。